Vaccines for cervical cancer

Epidemiology and Infection

Volumn 134, Issue 1, 2006, Pages 1-12

  Lowndes, C M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; DNA VACCINE; PLACEBO; VIRUS VACCINE;

CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; CYTOLOGY; DEVELOPING COUNTRY; DRUG EFFICACY; EUROPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION PREVENTION; INFECTION RISK; MORBIDITY; NONHUMAN; NORTH AMERICA; PAPANICOLAOU TEST; PREVALENCE; PRIMARY PREVENTION; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION;

CANCER VACCINES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 30844452024     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268805005728     Document Type: Review

References (74)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: The global picture. Eur J Cancer 2001; 37 (Suppl 8): S4-S66.
2. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265.
3. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, version 2.0. IARC Press, Lyon, 2004 (http://www-depdb.iarc.fr/globocan/ GLOBOframe.htm). Accessed 2 July 2005.
4. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9: 37-48.
5. Kiviat N, Koutsky LA, Paavonen J. Cervical neoplasia and other STD-related genital tract neoplasias. In: Holmes KK, Sparling PF, Mardh P-A, Lemon SM, Stamm WE, Piot P, Wasserheit JN, eds. Sexually transmitted diseases, chapter 49. New York, McGraw-Hill, 1999: 669-684.
6. Zheng T, Holford TR, Ma Z, Chen Y, Liu W, Ward BA, Boyle P. The continuing increase in adenocarcinoma of the uterine cervix: A birth cohort phenomenon. Int J Epidemiol 1996; 25: 252-258.
7. Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001; 357: 1490-1493.
8. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: Epidemiology, prevention and the role of human papillomavirus infection. Can Med Assoc J 2001; 164: 1017-1025.
9. Lehtinen M, Paavonen J. Efficacy of preventive human papillomavirus vaccination. Int J STD AIDS 2001; 12: 771-776.
10. Gillison ML, Shah KV. Role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr 2003; 31: 57-65.
11. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study. Lancet 2001; 357: 1831-1836.
12. Burk RD, Kelly P, Feldman J, et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996; 23: 333-341.
13. Dillner J, Kallings I, Brihmer C, et al. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996; 173: 1394-1398.
14. Koutsky LA, Kiviat NB. Genital human papillomaviruses. In: Holmes KK, Sparling PF, Mardh P-A, Lemon SM, Stamm WE, Piot P, Wasserheit JN, eds. Sexually transmitted diseases, chapter 49. New York, McGraw-Hill, 1999: 669-684.
15. Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population based prospective follow up study. BMJ 2002; 325: 572.
16. Karlsson R, Jonsson M, Edlund K, et al. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: A population-based study. Sex Transm Dis 1995; 22: 119-127.
17. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-428.
18. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180: 1415-1423.
19. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92: 464-474.
20. Rousseau MC, Villa LL, Costa MC, Abrahamowicz M, Rohan TE, Franco E. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex Transm Dis 2003; 30: 581-587.
21. Elfgren K, Kalantari M, Moberger B, Hagmar B, Dillner J. A population-based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol 2000; 183: 561-567.
22. Galloway DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis 2003; 3: 469-475.
23. Ho GY, Burk RD, Klien S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87: 1365-1371.
24. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796-802.
25. Munoz N, Bosch FX, de Sanjose S, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.
26. Lehtinen M, Paavonen J. Effectiveness of preventive human papillomavirus vaccination. Int J STD & AIDS 2003; 14: 787-792.
27. Anttila T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. J Am Med Assoc 2001; 285: 47-51.
28. Smith JS, Munoz N, Herrero R, et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 2002; 185: 324-331.
29. Lehtinen M, Koskela P, Jellum E, et al. Herpes simplex virus and risk of cervical cancer: A longitudinal, nested case-control study in the Nordic countries. Am J Epidemiol 2002; 156: 687-692.
30. Smith JS, Herrero R, Bosetti C, et al.; International Agency for Research on Cancer (IARC) Multicentric Cervical Cancer Study Group. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94: 1604-1613.
31. Zenilman JM. Chlamydia and cervical cancer: A real association? J Am Med Assoc 2001; 285: 81-83.
32. Hemminki K, Dong C, Vaittinen P. Familial risks in cervical cancer: Is there a hereditary component? Int J Cancer 1999; 82: 775-781.
33. Castellsague X, Bosch FX, Munoz N, et al.; International Agency for research on Cancer Multicenter Cervical Cancer Study Group. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346: 1105-1112.
34. Solomon D, Davey D, Kurman R, et al.; Forum Group Members; Bethesda 2001 Workshop. The 2001 Bethesda System: Terminology for reporting results of cervical cytology. J Am Med Assoc 2002; 287: 2114-2119.
35. Gustafsson L, Ponten J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997; 8: 755-763.
36. Levi F, Lucchini F, Negri E, Franceschi S, la Vecchia C. Cervical cancer mortality in young women in Europe: Patterns and trends. Eur J Cancer 2000; 36: 2266-2271.
37. Martin-Hirsch PL, Koliopoulos G, Paraskevaidis E. Is it now time to evaluate the true accuracy of cervical cytology screening? A review of the literature. Eur J Gynaecol Oncol 2002; 23: 363-365.
38. Hakama M, Hristova L. Effect of screening for cancer in the Nordic countries on deaths, costs and quality of life. Acta Oncol 1998; 36: 1-160.
39. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 249-256.
40. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Ann Intern Med 2000; 132: 810-819.
41. Crum CP. The beginning of the end for cervical cancer? N Engl J Med 2002; 347: 1703-1705.
42. European Commission DG V F.2. 'Europe against cancer' programme/ Committee on quality assurance, training and education of the European Federation of Cytology Societies (QUATE). European guidelines for quality assurance in cervical cancer screening, CRSG, 1997 (Technical editor: Dr Chris de Woolf). (http://crsg.ubc.kun.nl/quate/Guidelines/ euindex.html). Accessed 15 December 2002.
43. Laukkanen P, Koskela P, Pukkala E, et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 2003; 84: 2105-2109.
44. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: Clinical benefits and cost-effectiveness. J Am Med Assoc 2001; 285: 3107-3115.
45. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: The HART study. Lancet 2003; 362: 1871-1876.
46. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary. screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. J Am Med Assoc 2002; 288: 1749-1757.
47. Wright TC Jr., Cox JT, Massad LS, Twiggs LB, Wilkinson EJ; ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. J Am Med Assoc 2002; 287: 2120-2129.
48. Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: The Manchester cohort. Br J Cancer 2004; 91: 942-953.
49. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-1651.
50. Harper DM, Franco EL, Wheeler C, et al.; GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 2004; 364: 1757-1765.
51. Lehtinen M, Paavonen J. Vaccination against human papillomaviruses shows great promise. Lancet 2004; 364: 1731-1732.
52. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004; 2: 343-347.
53. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278.
54. Davidson EJ, Boswell CM, Sehr P, et al. Immunological and clinical responses in women with vulval intra-epithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003; 63: 6032-6041.
55. Kirnbauer R. Papillomavirus-like particles for serology and vaccine development. Intervirology 1996; 39: 54-61.
56. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-285.
57. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183: 8-15.
58. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002; 186: 737-742.
59. Thomas KK, Hughes JP, Kuypers JM, et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000; 182: 1097-1102.
60. Luostarinen T. No excess risk of cervical carcinoma among women seropositive for both HPV-16 and HPV6/11. Int J Cancer 1999; 80: 818-822.
61. Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci USA 1997; 94: 6571-6576.
62. Garnett GP, Waddell HC. Public health paradoxes and the epidemiological impact of an HPV vaccine. J Clin Virol 2000; 19: 101-111.
63. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13: 631-639.
64. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003; 106: 896-904.
65. Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. Br J Cancer 1996; 73: 1001-1005.
66. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. J Am Med Assoc 2003; 290: 781-789.
67. Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002; 325: 569.
68. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002; 186: 1396-1402.
69. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157: 218-226.
70. Taira AV. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 1915-1923.
71. Stanberry LR, Spruance SL, Cunningham U. et al.; GlaxoSmithKline Herpes Vaccine Efficacy Study Group. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347: 1652-1661.
72. Waller J, McCaffery K, Nazroo J, Wardle J. Making sense of information about HPV in cervical screening: A qualitative study. Br J Cancer 2005; 92: 265-270.
73. Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol 1998; 72: 6151-6154.
74. Gerber S, Lane C, Brown DM, et al. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol 2001; 75: 4752-4760.